Why Boehringer Ingelheim is embracing 'Research Beyond Borders' to drive organic growth




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Why Boehringer Ingelheim is embracing 'Research Beyond Borders' to drive organic growth
Released on: May 08, 2015. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    At their Annual Press Conference on April 22, 2015 in the Boehringer Ingelheim Center Prof Dr Andreas Barner, Chairman of the Board explained to PharmaVentures' Dr Fintan Walton how the research-driven pharmaceutical company is now positioned for future growth.
  • Summary
  • Transcript
  • Participants
  • Company
At their Annual Press Conference on April 22, 2015 in the Boehringer Ingelheim Center Prof Dr Andreas Barner, Chairman of the Board explained to PharmaVentures' Dr Fintan Walton how the research-driven pharmaceutical company is now positioned for future growth. “After a challenging 2014, the focus for us now is on launching numerous additional new products and on our profitability,” said Professor Andreas Barner.
At their Annual Press Conference on April 22, 2015 in the Boehringer Ingelheim Center Prof. Dr Andreas Barner, Chairman of the Board explained to PharmaVentures' Dr Fintan Walton how the research-driven pharmaceutical company is now positioned for future growth. “After a challenging 2014, the focus for us now is on launching numerous additional new products and on our profitability,” said Professor Andreas Barner.
Boehringer Ingelheim
Boehringer Ingelheim
Boehringer Ingelheim GmbH is a pharmaceutical company which concentrates on the development of human pharmaceuticals, biopharmaceuticals, chemicals, and animal health products. The Human Pharmaceuticals sector is the company's largest division, accounting for about 96% of sales. This includes prescription medicines and consumer healthcare products.